Trial Profile
Dose ranging study of S 44497 administered orally once daily for four weeks in type 2 diabetic patients. A multicentre, randomised, double-blind, double-dummy, phase II study versus placebo and glimepiride and sitagliptin.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2021
Price :
$35
*
At a glance
- Drugs S 44497 (Primary) ; Glimepiride; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 04 Sep 2021 This trial has been completed in Spain, according to European Clinical Trials Database.
- 29 Aug 2011 New trial record